ANNEXON, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
ANNEXON, INC. (ANNX) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations of $200.30 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2026-08-12
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $200.30M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $176.24M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $163.08M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $140.45M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations |
|---|---|
| 2026-06-30 | $200.30M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $176.24M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $163.08M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $140.45M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $133.32M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $98.15M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $50.53M 10-K · filed 2026-03-30 |
| 2024-09-30 | $80.57M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $158.34M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $152.97M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $226.14M 10-K · filed 2025-03-03 |
| 2023-09-30 | $134.19M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $114.65M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $145.15M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $141.05M 10-K · filed 2024-03-26 |
| 2022-09-30 | $211.69M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $105.65M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $113.99M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $76.01M 10-K · filed 2023-03-06 |
| 2021-09-30 | $69.69M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $100.75M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $207.84M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $268.56M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |